Bradmer Pharmaceuticals Inc. (TSE:GLX – Get Free Report) has received a consensus recommendation of “Strong Buy” from the seven ratings firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and six have assigned a strong buy recommendation to the company.
Separately, Citizens Jmp upgraded shares of Bradmer Pharmaceuticals to a “strong-buy” rating in a report on Tuesday, December 9th.
View Our Latest Analysis on GLX
Bradmer Pharmaceuticals Stock Performance
Featured Articles
- Five stocks we like better than Bradmer Pharmaceuticals
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- A U.S. “birthright” claim worth trillions – activated quietly
- Ticker Revealed: Pre-IPO Access to “Next Elon Musk” Company
- First Time Since 2007: All Warnings Active
- How the Rich Retire
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
